Xiaokang Zhang

Zhang Xiaokang graduated from Tongji Medical College of Huazhong University of Science and Technology, majoring in clinical medicine, and has worked for more than 8 years in ICON Clinical Research, a CRO company. He participated in and was responsible for more than 25 Phase I trials, more than 5 Phase II and III global and Asia-Pacific trials, and developed from clinical supervisor to clinical trial manager and global project manager. After joining Janssen Company, he organized and carried out a number of phase IIB and phase III global and Asia-Pacific multi-center clinical trials in the field of blood tumors and solid tumors, including lymphoma, multiple myeloma (monoclonal antibody drugs and CAR-T cell therapy), prostate cancer, etc.